# Oleclumab

Source: https://onco.cc/drugs/oleclumab/  
OnCo record `oleclumab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Oleclumab is an experimental investigational agent whose form is not stated in the registry from AstraZeneca in phase 3 trials for non-small-cell lung cancer, triple-negative breast cancer and colorectal cancer, with its target not yet stated publicly.

## Summary

Oleclumab (MEDI9447) is an investigational agent whose form is not stated in the registry developed by AstraZeneca and MedImmune. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Participants will receive oleclumab in combination with osimertinib or AZD4635 as stated in the arms' description. It is the investigational product in 7 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05221840 (A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer), in non-small-cell lung cancer, triple-negative breast cancer and colorectal cancer. The largest, NCT05221840, plans to enrol 1051 participants (actual) with primary completion expected 2026-09-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: MEDI9447
- Modality: antibody (INN stem -mab; form not stated in the registry record)
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Notes

- Oleclumab (MEDI9447) is a monoclonal antibody against the ectoenzyme CD73, also called ecto-5'-nucleotidase, which converts AMP to adenosine; blocking it lowers free adenosine and lifts adenosine-mediated suppression of CD8 T cells (NCI Drug Dictionary). CD73 has no target record in the corpus yet.

## Sources

- ClinicalTrials.gov: trials of Oleclumab: https://clinicaltrials.gov/search?intr=MEDI9447
- NCI Drug Dictionary: oleclumab: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/oleclumab

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- trials: [A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05221840/), [A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer](https://onco.cc/trials/nct03742102/), [A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small ](https://onco.cc/trials/nct06606847/), [COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC](https://onco.cc/trials/nct04068610/), [Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer](https://onco.cc/trials/nct05061550/), [Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study](https://onco.cc/trials/nct03381274/), [Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy](https://onco.cc/trials/nct03334617/), [The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2](https://onco.cc/trials/nct07146230/)

---
JSON: https://onco.cc/api/v1/entities/oleclumab.json